Paracetamol Combino Pharm (Paracetamol)

Paracetamol acts mainly by inhibiting cyclooxygenase enzymes, particularly COX‑2, within the central nervous system. This inhibition reduces the synthesis of prostaglandins that sensitize pain pathways and reset the hypothalamic set‑point for temperature regulation, thereby providing analgesic and antipyretic effects without significant peripheral anti‑inflammatory activity.

The dosage of Paracetamol Combino Pharm is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and liver function. Healthcare professionals calculate the appropriate infusion rate and total amount in accordance with local guidelines and the product’s prescribing information.

Paracetamol is generally considered the analgesic/antipyretic of choice during pregnancy and lactation when used at recommended doses, but safety depends on individual clinical assessment. Pregnant or nursing patients should only receive the product if the prescriber determines that the potential benefits outweigh any possible risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.

Compared with non‑steroidal anti‑inflammatory drugs (NSAIDs), intravenous paracetamol offers analgesic and antipyretic benefits without the gastrointestinal or platelet‑inhibiting side effects typical of NSAIDs. Unlike opioids, it does not cause respiratory depression or dependence, making it a useful option for moderate pain when a non‑opioid approach is preferred.

The product should be stored at 2 °C to 8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration, and allow it to reach room temperature if required for infusion, following aseptic technique.

Paracetamol Combino Pharm is given by intravenous infusion, typically diluted in a compatible carrier fluid and administered over a specified period as directed by the prescriber. Administration should be performed by qualified healthcare personnel using aseptic techniques and appropriate infusion equipment to ensure accurate dosing and patient safety.

The most serious risks include severe hepatotoxicity, which can lead to acute liver failure, especially in cases of overdose or pre‑existing liver disease, and rare hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Prompt recognition and discontinuation of the drug are essential if these events occur.

Paracetamol Combino Pharm should be avoided in patients with known hypersensitivity to paracetamol or any excipients, in individuals with severe hepatic impairment, and in those who have experienced serious adverse reactions such as anaphylaxis or severe skin reactions to paracetamol. Contraindications should be confirmed by the treating clinician before initiation.